TIN-816 is under clinical development by and currently in Phase II for Acute Renal Failure (ARF) (Acute Kidney Injury). According to GlobalData, Phase II drugs for Acute Renal Failure (ARF) (Acute Kidney Injury) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TIN-816 LoA Report.

Smarter leaders trust GlobalData

Data Insights

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TIN-816 overview

TIN-816 is under development for the treatment of sepsis associated acute kidney injury (SA-AKI) and acute kidney injury following cardiac surgery. It is administered through intravenous route in the form of powder. The drug candidate acts by targeting adenosine triphosphatase (ATP).

See Also:

Novartis overview

is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. is headquartered in Basel, Switzerland.

For a complete picture of TIN-816’s drug-specific PTSR and LoA scores,

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData鈥檚 Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData鈥檚 .